Celsion to Hold Third Quarter 2009 Financial Results Conference Call Tuesday, November 10, 2009
COLUMBIA, Md., Nov 06, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a late stage clinical oncology development company that is leveraging its heat activated liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it will hold a conference call to discuss third quarter 2009 results at 11:00 a.m. Eastern Time on Tuesday, November 10, 2009. To participate in the call, interested parties may dial 1-877-852-6580 or 1-719-325-4751 (International) and use Conference ID: 2474093 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com
The call will be archived for replay on November 10, 2009 at 2:00 p.m. and will remain available until November 17, 2009. The replay can be accessed at 1-888-203-1112 or 1-719-457-0820 (International) using Conference ID: # 2474093. The call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2:00 P.M. on Tuesday, November 10, 2009.
About Celsion Corporation
Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox(R) to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.
For more information on Celsion, visit our website: http://www.celsion.com
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
ThermoDox(R) is a registered trademark of Celsion Corporation
SOURCE: Celsion Corporation
Celsion Corporation
Sean Moran, 410-290-5390
Senior Vice President and Chief Financial Officer
smoran@celsion.com
or
The Trout Group
Marcy Nanus, 646-378-2927
mnanus@troutgroup.com
Copyright Business Wire 2009
